Patient characteristics and outcome for eligible patients on AAML0431
Characteristic . | All patients, n = 204 . | AML, n = 144 . | MDS, n = 60 . | AML vs MDS . | |||
---|---|---|---|---|---|---|---|
N . | % . | N . | % . | N . | % . | P . | |
Sex | |||||||
Male | 99 | 48.5 | 73 | 50.7 | 26 | 43.3 | .338 |
Female | 105 | 51.5 | 71 | 49.3 | 34 | 56.7 | |
Race | |||||||
Asian | 12 | 6.6 | 9 | 7.0 | 3 | 5.6 | 1.000 |
Native Hawaiian or other Pacific Islander | 2 | 1.1 | 2 | 1.6 | 0 | 0.0 | 1.000 |
Black or African American | 28 | 15.4 | 21 | 16.4 | 7 | 13.0 | .556 |
White | 140 | 76.9 | 96 | 75.0 | 44 | 81.5 | .343 |
Unknown | 22 | 16 | 6 | ||||
Ethnicity | |||||||
Hispanic | 48 | 9.6 | 32 | 22.7 | 16 | 26.7 | .546 |
Not Hispanic | 153 | 90.4 | 109 | 77.3 | 44 | 73.3 | |
Unknown | 3 | 3 | 0 | ||||
History of TMD | |||||||
No | 141 | 69.1 | 103 | 71.5 | 38 | 63.3 | .248 |
Yes | 63 | 30.9 | 41 | 28.5 | 22 | 36.7 | |
Received prior treatment of TMD | |||||||
No | 198 | 97.1 | 141 | 97.9 | 57 | 95.0 | .362 |
Yes | 6 | 2.9 | 3 | 2.1 | 3 | 5.0 | |
FAB | |||||||
M0 | 3 | 1.5 | 3 | 2.1 | 0 | 0.0 | * |
M1 | 5 | 2.5 | 5 | 3.5 | 0 | 0.0 | * |
M2 | 7 | 3.4 | 7 | 4.9 | 0 | 0.0 | * |
M5 | 1 | 0.5 | 1 | 0.7 | 0 | 0.0 | * |
M6 | 3 | 1.5 | 3 | 2.1 | 0 | 0.0 | * |
M7 | 85 | 41.7 | 85 | 59.0 | 0 | 0.0 | * |
AML not further classified | 40 | 19.6 | 40 | 27.8 | 0 | 0.0 | * |
MDS refractory anemia | 3 | 1.5 | 0 | 0.0 | 3 | 5.0 | * |
MDS RA with excess blasts | 18 | 8.8 | 0 | 0.0 | 18 | 30.0 | * |
MDS RAEB in transformation | 6 | 2.9 | 0 | 0.0 | 6 | 10.0 | * |
MDS not further classified | 33 | 16.2 | 0 | 0.0 | 33 | 55.0 | * |
Cytogenetic classification | |||||||
Normal (trisomy 21 only) | 52 | 28.0 | 37 | 28.2 | 15 | 27.3 | .893 |
Monosomy 7 | 3 | 1.6 | 2 | 1.5 | 1 | 1.8 | 1.000 |
Del(7q) only | 5 | 2.7 | 3 | 2.3 | 2 | 3.6 | .633 |
Monosomy 5/del(5q) | 3 | 1.6 | 3 | 2.3 | 0 | 0.0 | .556 |
+8 | 49 | 26.3 | 35 | 26.7 | 14 | 25.5 | .858 |
Multiple trisomy 21 | 25 | 13.4 | 22 | 16.8 | 3 | 5.5 | .039† |
Trisomy 21 with other abnormalities | 49 | 26.3 | 29 | 22.1 | 20 | 36.4 | .044† |
Unknown | 18 | 13 | 5 | ||||
Age from diagnosis, (median, range), y | 1.59 | (0.38-3.78) | 1.7 | (0.38-3.75) | 1.42 | (0.53-3.78) | .036† |
WBC, (median, range), ×109/L | 5.75 | (1.6-118.3) | 6.5 | (1.6-118.3) | 4.9 | (1.6-28.6) | <.001† |
Platelets, (median, range), ×109/L | 34.5 | (2.0-1280) | 34 | (2-1280) | 36.5 | (3-176) | .716 |
Peripheral blasts, (median, range), % | 3.55 | (0-89) | 7 | (0-89) | 0 | (0-31) | <.001† |
Outcome, from study entry | |||||||
5-y EFS | 89.9 | 95% CI: 84.8-93.4 | 88.6 | 95% CI: 82.0-92.8 | 93.2 | 95% CI: 82.9-97.4 | .329 |
5-y OS | 93 | 95% CI: 88.5-95.8 | 92.2 | 95% CI: 86.4-95.6 | 94.9 | 95% CI: 85.1-98.3 | .492 |
Characteristic . | All patients, n = 204 . | AML, n = 144 . | MDS, n = 60 . | AML vs MDS . | |||
---|---|---|---|---|---|---|---|
N . | % . | N . | % . | N . | % . | P . | |
Sex | |||||||
Male | 99 | 48.5 | 73 | 50.7 | 26 | 43.3 | .338 |
Female | 105 | 51.5 | 71 | 49.3 | 34 | 56.7 | |
Race | |||||||
Asian | 12 | 6.6 | 9 | 7.0 | 3 | 5.6 | 1.000 |
Native Hawaiian or other Pacific Islander | 2 | 1.1 | 2 | 1.6 | 0 | 0.0 | 1.000 |
Black or African American | 28 | 15.4 | 21 | 16.4 | 7 | 13.0 | .556 |
White | 140 | 76.9 | 96 | 75.0 | 44 | 81.5 | .343 |
Unknown | 22 | 16 | 6 | ||||
Ethnicity | |||||||
Hispanic | 48 | 9.6 | 32 | 22.7 | 16 | 26.7 | .546 |
Not Hispanic | 153 | 90.4 | 109 | 77.3 | 44 | 73.3 | |
Unknown | 3 | 3 | 0 | ||||
History of TMD | |||||||
No | 141 | 69.1 | 103 | 71.5 | 38 | 63.3 | .248 |
Yes | 63 | 30.9 | 41 | 28.5 | 22 | 36.7 | |
Received prior treatment of TMD | |||||||
No | 198 | 97.1 | 141 | 97.9 | 57 | 95.0 | .362 |
Yes | 6 | 2.9 | 3 | 2.1 | 3 | 5.0 | |
FAB | |||||||
M0 | 3 | 1.5 | 3 | 2.1 | 0 | 0.0 | * |
M1 | 5 | 2.5 | 5 | 3.5 | 0 | 0.0 | * |
M2 | 7 | 3.4 | 7 | 4.9 | 0 | 0.0 | * |
M5 | 1 | 0.5 | 1 | 0.7 | 0 | 0.0 | * |
M6 | 3 | 1.5 | 3 | 2.1 | 0 | 0.0 | * |
M7 | 85 | 41.7 | 85 | 59.0 | 0 | 0.0 | * |
AML not further classified | 40 | 19.6 | 40 | 27.8 | 0 | 0.0 | * |
MDS refractory anemia | 3 | 1.5 | 0 | 0.0 | 3 | 5.0 | * |
MDS RA with excess blasts | 18 | 8.8 | 0 | 0.0 | 18 | 30.0 | * |
MDS RAEB in transformation | 6 | 2.9 | 0 | 0.0 | 6 | 10.0 | * |
MDS not further classified | 33 | 16.2 | 0 | 0.0 | 33 | 55.0 | * |
Cytogenetic classification | |||||||
Normal (trisomy 21 only) | 52 | 28.0 | 37 | 28.2 | 15 | 27.3 | .893 |
Monosomy 7 | 3 | 1.6 | 2 | 1.5 | 1 | 1.8 | 1.000 |
Del(7q) only | 5 | 2.7 | 3 | 2.3 | 2 | 3.6 | .633 |
Monosomy 5/del(5q) | 3 | 1.6 | 3 | 2.3 | 0 | 0.0 | .556 |
+8 | 49 | 26.3 | 35 | 26.7 | 14 | 25.5 | .858 |
Multiple trisomy 21 | 25 | 13.4 | 22 | 16.8 | 3 | 5.5 | .039† |
Trisomy 21 with other abnormalities | 49 | 26.3 | 29 | 22.1 | 20 | 36.4 | .044† |
Unknown | 18 | 13 | 5 | ||||
Age from diagnosis, (median, range), y | 1.59 | (0.38-3.78) | 1.7 | (0.38-3.75) | 1.42 | (0.53-3.78) | .036† |
WBC, (median, range), ×109/L | 5.75 | (1.6-118.3) | 6.5 | (1.6-118.3) | 4.9 | (1.6-28.6) | <.001† |
Platelets, (median, range), ×109/L | 34.5 | (2.0-1280) | 34 | (2-1280) | 36.5 | (3-176) | .716 |
Peripheral blasts, (median, range), % | 3.55 | (0-89) | 7 | (0-89) | 0 | (0-31) | <.001† |
Outcome, from study entry | |||||||
5-y EFS | 89.9 | 95% CI: 84.8-93.4 | 88.6 | 95% CI: 82.0-92.8 | 93.2 | 95% CI: 82.9-97.4 | .329 |
5-y OS | 93 | 95% CI: 88.5-95.8 | 92.2 | 95% CI: 86.4-95.6 | 94.9 | 95% CI: 85.1-98.3 | .492 |